Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its 2013 Annual Report and 2013 Annual Summary for the fiscal year ended December 31, 2013. The filing, dated February 27, 2014, serves to notify shareholders and the SEC of the availability of these documents and includes the 2014 Notice of Annual General Meeting. The unaudited Preliminary Results for the year were previously announced on February 5, 2014.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced 2013 Annual Report and Preliminary Results announcement, which are not included in this document.
However, the filing does disclose the following dividend schedule for 2014 and 2015:
- Q4 2013 Dividend: Ex-dividend date February 19, 2014; Payment date April 10, 2014.
- Q1 2014 Dividend: Ex-dividend date May 14, 2014; Payment date July 10, 2014.
- Q2 2014 Dividend: Ex-dividend date August 6, 2014; Payment date October 2, 2014.
- Q3 2014 Dividend: Ex-dividend date November 5, 2014; Payment date January 8, 2015.
Material Changes and Unusual Items
The filing does not detail specific material changes in financial performance compared to the prior period. It notes that the company operates in a highly competitive and regulated global industry. A significant historical context mentioned is a $3 billion payment in 2012 to resolve US government investigations focused on promotional practices. Additionally, the company disclosed an incident in 2013 involving scientific data misrepresentation in a 2010 publication, which was retracted, leading to improved controls in R&D.
Guidance, Outlook, Risks, and Contingencies
The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties. The Appendix details principal risks and uncertainties, including:
- Intellectual Property: Risks related to patent expirations, specifically noting the uncertainty regarding generic competition for Seretide/Advair in the US market, despite a device patent expiring in August 2016.
- Legal and Regulatory: Exposure to product liability, antitrust, and sales/marketing litigation. The company is a defendant in various lawsuits, including class actions.
- Product Safety and Quality: Risks of adverse events, product recalls, and failure to comply with Good Manufacturing Practice (GMP).
- Supply Chain: Risks of supply interruption due to single-source dependencies or regulatory non-compliance.
- Tax and Treasury: Risks associated with changing tax laws, transfer pricing, and treasury activities.
- Commercial Practices: Risks related to compliance with laws governing interactions with healthcare professionals and promotional activities.
Management has outlined mitigating activities for each risk, including enhanced medical governance, a global Quality Management System, and a centralized intellectual property model to reduce transfer pricing risks.
Investor Verification Checklist
- Verify the specific revenue, profit, and cash flow figures in the full 2013 Annual Report and the February 5, 2014 Preliminary Results announcement.
- Review Note 44 ('Legal proceedings') in the 2013 Annual Report for details on unresolved disputes and potential litigation liabilities.
- Examine pages 229-231 of the 2013 Annual Report for patent expiration dates of major products.
- Confirm the status of the $3 billion settlement from 2012 and any ongoing regulatory investigations.
- Assess the impact of the 2013 scientific data misrepresentation incident on R&D pipeline integrity and future regulatory filings.